| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
MMP-1/3
Cordycepin targets multiple pathways. It is a nucleoside antagonist that inhibits RNA synthesis by causing premature termination of transcription. It has displayed cytotoxicity against some leukemic cell lines in vitro. It possesses a wide range of biological activities. |
|---|---|
| ln Vitro |
Cordycepin substantially bursts the p38/JNK/AP-1 signaling pathway in RASF and suppresses the generation of chemokines and MMP expression that are triggered by IL-1β. The MTT assay was employed to assess cordycepin's impact on RASF cytotoxicity. Cell viability of RASF treated with cordycepin (50 μM or 100 μM) did not alter significantly during the course of the 24-hour treatment. On the other hand, cell viability was recovered after 48 hours after treatment with 100 μM cordycepin [1].
In vitro, Cordycepin has displayed cytotoxicity against some leukemic cell lines. It possesses immunological stimulating, anti-hyperglycemia, anti-cancer, neuroprotective, antifungal, antibacterial, anti-inflammatory, anti-virus, and anti-infection activities. |
| ln Vivo |
In vivo, Cordycepin has been studied for its various biological activities, including anti-cancer and anti-inflammatory effects. At least one clinical trial of cordycepin has been conducted. It has anti-hyperglycemia activity.
|
| Enzyme Assay |
ELISA of chemokines[1]
RASFs were pre-treated with cordycepin (50 μM and 100 μM) for 1 h and then incubated with IL-1β (5 ng/ml). After 24 h, culture medium was collected and centrifuged at 10 000 g for 5 min at 4°C to remove particulates. Quantities of RANTES, ENA-78, MCP-1 and GRO-α were determined using Quantikine ELISA kits. Optical density was determined with Microplate reader. A standard curve of each cytokine was established using known concentrations of cytokine by plotting optical density vs log of the concentration.[1] Cordycepin is an efficient component of Cordyceps spp, a traditional Chinese medicine widely used for healthcare in China, and has been recently acted as a strong anticancer agent for clinic. However, whether and how it may play a role in combating tuberculosis, caused by Mycobacterium tuberculosis, remains unknown. Here we report that cordycepin can kill Mycobacterium by hijacking the bacterial adenosine kinase (AdoK), a purine salvage enzyme responsible for the phosphorylation of adenosine (Ado) to adenosine monophosphate (AMP). We show that cordycepin is a poor AdoK substrate but it competitively inhibits the catalytic activity of AdoK for adenosine phosphorylation. Cordycepin does not affect the activity of the human adenosine kinase (hAdoK), whereas hAdoK phosphorylates cordycepin to produce a new monophosphate derivative. Co-use of cordycepin and deoxycoformycin, an inhibitor of adenosine deaminase (ADD), more efficiently kills M. bovis and M. tuberculosis. The add-deleted mycobacterium is more sensitive to cordycepin. This study characterized cordycepin as a new mycobactericidal compound and also uncovered a potential anti-mycobacterial mechanism[2]. Cordycepin is evaluated in cell-free assays to study its mechanism of action as a nucleoside antagonist. It can be used as a standard in biochemical assays. Its purity and identity can be confirmed using HPLC and NMR analysis. |
| Cell Assay |
Determination of cell viability[1]
RASFs (2 × l04 cells/well) were treated with various concentrations of cordycepin. After incubation for 1 h, 12 h and 24 h, cells were washed twice with PBS, MTT (0.5 mg/ml PBS) was added to each well and incubated at 37°C for 30 min. Formazan crystals formed were dissolved by adding DMSO (100 μl/well) and the absorbance was read at 570 nm using a microplate reader[1]. Western blot analysis[1] RASFs (5 × 106 cells) were pre-treated with cordycepin for 1 h and then incubated with IL-1β (5 ng/ml) or TNF-α (5 ng/ml) for 24 h. Cells were lysed with 40 μl of ice-cold lysis buffer (50 mM Tris–HCl pH 7.4, 1% NP-40, 0.5% sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 0.1% SDS). Samples were separated by SDS–PAGE with 10% polyacrylamide gels and electrotransferred into polyvinylidene fluoride (PVDF). The PVDF membranes were blotted with 1 μg/ml of primary antibodies for p38, p-p38, JNK, p-JNK, ERK, p-ERK, β-actin, MMP-1 and MMP-3. HRP-conjugated IgG was used as a secondary antibody. The protein expression levels were then determined by analysing the signals captured on the PVDF membranes using an image analyser Cordycepin is assessed in cell-based assays using leukemic cell lines and other cancer cells. Cells are treated with Cordycepin, and cell proliferation, apoptosis, and RNA synthesis are measured. Its antiviral, antibacterial, and antifungal activities are evaluated in appropriate cell culture models. |
| Animal Protocol |
Cordycepin is administered in animal models to evaluate its various biological activities. It has been studied for its anti-cancer, anti-inflammatory, and neuroprotective effects.
|
| ADME/Pharmacokinetics |
Coelenterazine H has a molecular weight of 407.46 and a molecular formula of C26H21N3O2. It has a CAS number of 50909-86-9. The compound is soluble in DMSO at up to 10 mg/ml and in methanol at up to 1 mg/ml. It should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Coelenterazine H. The compound is for research use only and is not intended for human therapeutic use. It is a luminescent substrate used in bioluminescence assays and imaging.
|
| References | |
| Additional Infomation |
Cordycepin is a 3'-deoxynucleoside belonging to the adenosine class of compounds. It possesses antimetabolite and nucleoside antibiotic activity. Cordycepin has been used in clinical trials for the treatment of leukemia. It has been reported to be found in Cordyceps militaris, Streptomyces sparserifolium, and other organisms with relevant data. Cordycepin is a purine nucleoside antimetabolite and antibiotic isolated from Cordyceps militaris, possessing potential antitumor, antioxidant, and anti-inflammatory activities. Cordycepin can inhibit polyadenylation, activate AMP-activated protein kinase (AMPK), and reduce the mammalian target of rapamycin (mTOR) signaling pathway, which may lead to tumor cell apoptosis and reduced tumor cell proliferation. mTOR is a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-associated kinase (PIKK) family, playing a crucial role in the PI3K/AKT/mTOR signaling pathway regulating cell growth and proliferation; its expression or activity is frequently dysregulated in human cancers.
Coelenterazine H is also known as 2-Deoxycoelenterazine and CLZN-h. It is a naturally occurring luciferin found in bioluminescent organisms such as jellyfish, sea pansies, and copepods. It is used as a tool for imaging and detection of biological molecules. The compound is not approved for clinical use. |
| Molecular Formula |
C10H13N5O3
|
|---|---|
| Molecular Weight |
251.24
|
| Exact Mass |
251.101
|
| Elemental Analysis |
C, 47.81; H, 5.22; N, 27.87; O, 19.10
|
| CAS # |
73-03-0
|
| Related CAS # |
73-03-0;
|
| PubChem CID |
6303
|
| Appearance |
White to off-white solid powder
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
627.2±65.0 °C at 760 mmHg
|
| Melting Point |
225-229ºC
|
| Flash Point |
333.1±34.3 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.863
|
| LogP |
-0.41
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
307
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O1[C@]([H])(C([H])([H])O[H])C([H])([H])[C@]([H])([C@]1([H])N1C([H])=NC2=C(N([H])[H])N=C([H])N=C12)O[H]
|
| InChi Key |
OFEZSBMBBKLLBJ-BAJZRUMYSA-N
|
| InChi Code |
InChI=1S/C10H13N5O3/c11-8-7-9(13-3-12-8)15(4-14-7)10-6(17)1-5(2-16)18-10/h3-6,10,16-17H,1-2H2,(H2,11,12,13)/t5-,6+,10+/m0/s1
|
| Chemical Name |
(2R,3R,5S)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
|
| Synonyms |
9(3DeoxyDribofuranosyl)adenine; Cordycepin; 3'-Deoxyadenosine; 73-03-0; Cordycepine; 9-Cordyceposidoadenine; ADENOSINE, 3'-DEOXY-; 9-(beta-D-3'-Deoxyribofuranosyl)adenine; (2R,3R,5S)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3-ol; 3Deoxyadenosine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~132.66 mM)
H2O : ~2 mg/mL (~7.96 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5.56 mg/mL (22.13 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9803 mL | 19.9013 mL | 39.8026 mL | |
| 5 mM | 0.7961 mL | 3.9803 mL | 7.9605 mL | |
| 10 mM | 0.3980 mL | 1.9901 mL | 3.9803 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA